BeiGene and BeiZeAn are approved for new indications in the United States
六月清晨搅
发表于 2024-12-31 14:35:57
183
0
0
Recently, BeiGene announced that the US Food and Drug Administration (FDA) has approved the use of BeiGene (Trastuzumab) in combination with platinum and fluorouracil chemotherapy for first-line treatment of adult patients with unresectable or metastatic HER2 negative gastric or gastroesophageal junction (G/GEJ) cancer expressing PD-L1 (≥ 1).
Logomoney.com 情報発信プラットフォームであり、情報保存空間サービスのみを提供しています。
本文はLogomoney.comの立場を代表するものではなく、提案を構成するものではありません、慎重に対応してください。
本文はLogomoney.comの立場を代表するものではなく、提案を構成するものではありません、慎重に対応してください。
あなたが好きだと思う
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Lilly's Alzheimer's disease drug Kisunla approved for sale in the UK
- Puyin International: downgraded BeiGene A-share rating to 'hold', maintaining target price of 181 yuan
- BeiGene: Several new indications for commercial products have been included in the 2024 National Medical Insurance Drug Catalog
- AbbVie: Two new indications for Ruifu (Upatinib Extended Release Tablets) have been added to the national medical insurance catalog in China
- Multiple new indications for Merck drugs approved for market in China
- BeiGene: NASDAQ stock code will be changed to 'ONC'
- BeiGene NASDAQ stock code will be changed to 'ONC'
- BeiGene issues 100000 shares, with an increase of 0.007%